Pfizer and Anumana boost detection of cardiovascular disease
Partnership will support development of new algorithm and identify at risk patients
Read More
Tag: cardiovascular
US approval for MSD’s heart failure med Verquvo
Drug approved to reduce the risk of cardiovascular death/heart failure hospitalisation
Read More
MSD/Pfizer’s diabetes drug Steglatro hits goal in CV outcomes trial
The drug was shown to be as safe as placebo on a composite of CV death, nonfatal myocardial infarction or nonfatal stroke
Read More
Novartis, NHS strike ‘innovative’ cardiovascular deal
Novartis’ inclisiran will be studied in UK patients as part of a large-scale NHS clinical trial, which is expected to start later this year.
Read More
NHS to review making statins available for pharmacists
If only 45% of people with a high risk of cardiovascular disease were identified and treated, 6,000 strokes and heart attacks could be avoided over the next ten years.
Read More
Brilinta reduces CV events but increases bleeding
The drug reduced the relative risk for the composite of cardiovascular death, heart attack, or stroke by 10% compared with aspirin alone.
Read More
Invokana hits endpoints in cardiovascular trial
A sub-group analysis found that the Janssen drug provided consistent CV and renal protection.
Read More
AZ confirms cardiovascular safety with roxadustat results
The companies will begin discussions with the US Food and Drug Administration (FDA) to prepare for regulatory submission.
Read More
Novo Nordisk launches type II diabetes awareness campaign
Novo Nordisk UK is launching a campaign to raise awareness of the risk of heart attacks and strokes in people living with type II diabetes.
Read More
AZ’ Tudorza hits study goals in COPD patients with CV risk factors
AstraZeneca says top-line results from a post-marketing study show that Tudorza Pressair is effective in reducing chronic obstructive pulmonary disease (COPD) exacerbations in patients with cardiovascular issues.
Read More
Ten percent of men have ‘older’ hearts
A new analysis from Public Health England shows that one in 10 men have a heart age 10 years older than they are, increasing their risk for heart attack or stroke.
Read More
Extended use of AZ’ Brilinta cuts CV death risk 29%
Long-term use of AstraZeneca’s Brilinta in patients with a history of heart attack reduces the risk of cardiovascular death by 29 percent, a new sub analysis of data from the Phase III PEGASUS-TIMI 54 trial has found.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
